Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of January 2022, with the filing date of January 4, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory notifications rather than financial performance data.
Material Changes
The primary material event disclosed is the cessation of securities trading for the ticker symbol "ATH," as indicated by Exhibit 99.1. No financial comparisons to prior periods are included in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities into the company's existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the reason for its cessation.
- Confirm the impact of the cessation on the company's existing Registration Statements (S-8 and F-3).
- Review subsequent filings for updated financial data, as this report contains no financial metrics.